Endocrinology · 2 h ago
Cambridge team reports compact optical spectrometer with early biomarker demonstrations
A study in *Nature Photonics* describes a silicon nitride convolutional spectrometer operating across near-infrared wavelengths of 1200–1700 nm. The researchers report laboratory tests involving material identification and biomarker measurements, including a prolonged noninvasive glucose demonstration in one participant; clinical performance has not been established.
- Compact spectrometer operates at 1200–1700 nm.
- Reported 100% classification in tested materials.
- Noninvasive glucose tracking demonstrated in one participant.
- Clinical validation and broader testing remain necessary.
Researchers from the University of Cambridge and GlitterinTech developed and tested a compact optical spectrometer that uses a convolution-based design to analyze light. Built on a silicon nitride photonic platform with onboard electronics, it operates at 1200–1700 nm and processes measurements in under a second. The source reports an estimated device cost of about $10.
In reported tests, the device classified plastics, pharmaceuticals, coffee, flour and tea with 100% success. It measured concentrations in water-based and organic solutions with approximately 0.01% accuracy. The team also demonstrated measurements of skin moisture, blood alcohol, lactate and glucose under conditions intended to reflect physiological environments. Noninvasive glucose tracking was shown over an extended period in one participant.
These are early technical demonstrations, not evidence of validated clinical performance or a ready-to-use glucose monitor. The source provides no participant count beyond the single-person glucose demonstration, and does not describe clinical diagnostic comparisons or performance across a patient population. Further testing is needed before the technology could support medical use. Claims about low cost and potential wearable applications should therefore be understood as prospective.
In practice
The report describes a technical proof of concept for optical biomarker sensing, including noninvasive glucose tracking over time in one participant. It does not establish accuracy, safety, or reliability for diabetes management in a clinical population, and the source provides no basis for replacing established glucose-monitoring methods. The findings are promising for further device research but do not support a change in clinical practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Photonics (via ScienceDaily): Cambridge scientists create a $10 chip that could put a medical lab on your wrist ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.